培美曲赛联合铂类治疗晚期非小细胞肺癌的安全性和有效性观察

孙翠玲; 徐晓宇; 高莹莹; 谢小缺; 胡文军

doi:10.13898/j.cnki.issn.1000-2200.2015.06.018

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

培美曲赛联合铂类治疗晚期非小细胞肺癌的安全性和有效性观察

孙翠玲 , 徐晓宇 , 高莹莹 , 谢小缺 , 胡文军

文章导航 > 蚌埠医学院学报 > 2015, 40 > 6: (754-756)

引用本文:

Citation:

培美曲赛联合铂类治疗晚期非小细胞肺癌的安全性和有效性观察

安徽省阜阳市人民医院肿瘤科, 236000

作者简介: 孙翠玲(1974-),女,副主任医师.

中图分类号: R734.2

Safety and effectiveness of pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer

Department of Oncology, The People's Hospital of Fuyang, Fuyang Anhui 236000, China
CLC number: R734.2

摘要: 目的:探讨培美曲赛对初治或复治晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的安全性和有效性。方法:经病理学或细胞学确诊的晚期NSCLC患者41例, 其中一线治疗18例, 二线治疗23例。培美曲赛500 mg/m²(第1天)+顺铂25 mg/m²(第2、3、4天)或卡铂AUC=5(第1天)静脉滴注, 每3周为1个周期;评价安全性及有效性。结果:18例一线治疗患者中无完全缓解病例, 部分缓解7例, 稳定4例, 进展7例, 有效率38.89%, 疾病控制率61.11%, 中位无疾病进展时间6.8个月。23例二线治疗患者中无完全缓解病例, 部分缓解2例, 稳定9例, 进展12例, 有效率8.70%, 疾病控制率47.83%, 中位无进展生存时间2.6个月。2组主要不良反应为乏力、白细胞下降、贫血和胃肠道反应。结论:培美曲赛联合铂类方案一线、二线治疗晚期NSCLC疗效确切, 安全性高, 耐受性较好。
- 癌, 非小细胞肺 /
- 培美曲赛 /
- 顺铂 /
- 卡铂
Abstract: Objective:To investigate the safety and effectiveness of the pemetrexed in the treatment of the initial or recurrent advanced non-small cell lung cancer(NSCLC).Methods:The 18 cases of the first-line treatment and 23 cases of the secondary-line treatment in 41 cases with advanced NSCLC identified by pathology or cytology were treated with 500 mg/m² of pemetrexed at the first day combined with 25 mg/m² of cisplatin at 2, 3 and 4 days or 5 AUC of carboplatin at the first day by intravenous drip, 3 weeks for a course.The safety and effectiveness of treatment were evaluated.Results:Partial response in 7 cases, stabilization in 4 cases, progress in 7 cases and no complete response cases in 18 cases with the first-line treatment were found, the effective rate and disease control rate were 38.89% and 61.11%, respectively, and the median progression-free survival time of which was 6.8 months.Partial response in 2 cases, stabilization in 9 cases, progress in 12 cases and no complete response cases in 23 cases with the second-line treatment were found, the effective rate and disease control rate were 8.70% and 47.83%, respectively, and the median progression-free survival time of which was 2.6 months.The major adverse reactions in two groups included fatigue, white blood cells decreasing, anemia and gastrointestinal tract reaction.Conclusions:The effects of pemetrexed combined with platinum in the first-line and second-line treatment of advanced NSCLC are good, high safety and good tolerance.
- carcinoma,non-small cell lung /
- pemetrexed /
- cisplatin /
- carboplatin

[1]	孙燕,石远凯.内科肿瘤学[M].5版.北京:人民卫生出版社, 2007:161-162.
[2]	李江, 刘鸿生, 刘超英, 等.培美曲赛联合顺铂与多西他赛联合顺铂二线方案治疗晚期肺腺癌的临床对比研究[J].中华肿瘤防治杂志, 2010, 17(14):1127-1128.
[3]	张冠中, 焦顺昌.培美曲赛治疗非小细胞肺癌的研究进展[J].山东医药, 2011, 51(15):113-114.
[4]	吴尉,朱跃红,袁以军,等.吉西他滨或培美曲赛联合顺铂治疗晚期非小细胞肺癌的临床比较研究[J].临床和实验医学杂志, 2010,9(8):576-577.
[5]	Eisenhauer EA, Therasseb P, Bogaertsc J, et al.New respongse evaluation criteria in solid tumours:revised RECIST guideline(version 1.1) [J]. Eur J Cancer, 2009, 45(2):228-247.
[6]	Trotti A, Bentzen SM.The need for adverse effects reporting standards in oncology clinical trials[J].J Clin Oncol, 2004, 22(1):19-22.
[7]	Rossi A,Maione P,Bareschino MA,et al.The emerging role of hisology in the choice of first-line treatment of advanced nonsmall cell lung cancer:implication in the clinical decision-making[J].Curr Med Chem,2010,17(11):1030-1038.
[8]	Scagliotti GV,Parikh P,von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitatine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[9]	胡兴胜, 焦顺昌, 张树才, 等.培美曲赛及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究[J].中国肺癌杂志, 2012, 15(10):569-575.
[10]	王丽, 史美祺.培美曲赛联合铂类一线治疗晚期肺腺癌疗效[J].江苏医药, 2012, 38(11):1290-1292.
[11]	张玉梅, 李春姗, 陈逸恒.培美曲赛单药维持化疗晚期非小细胞肺癌的疗效观察[J].实用临床医药杂志, 2011, 15(13):48-50.
[12]	Adjei AA,Mandrekar SJ,Dy GK,et al.Phase Ⅱ trial of peme-trexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer:NCCTG and SWOG Study N0426[J].J Clin Oncol,2010,28(4):614-619.
[13]	狄杰, 周海燕.培美曲赛与多西紫杉醇二线治疗肺非鳞癌的临床比较[J].山东医药, 2011, 51(36):101-102.
[14]	韩金娣,方健,聂鋆.培美曲赛治疗晚期肺腺癌的疗效观察[J].中华肿瘤防治杂志, 2011, 18(21):1722-1724.

[1]	武文娟 , 陈丽 , 蒋亚齐 , 王朝敏 . 培美曲塞联合顺铂治疗晚期肺腺癌的疗效观察. 蚌埠医学院学报, 2015, 40(11): 1529-1531. doi: 10.13898/j.cnki.issn.1000-2200.2015.11.021
[2]	郑中显 , 吉兆宁 . 培美曲塞联合顺铂治疗老年晚期非小细胞肺癌患者32例疗效分析. 蚌埠医学院学报, 2011, 36(6): 610-611.
[3]	叶明明 , 胡文军 , 孙翠玲 , 周俭 . 多西他赛联合顺铂治疗中晚期非小细胞肺癌和乳腺癌临床观察. 蚌埠医学院学报, 2009, 34(8): 699-701.
[4]	汪济东 , 章银秀 , 许扬 , 周平 . 长春瑞滨加顺铂方案治疗晚期非小细胞肺癌25例分析. 蚌埠医学院学报, 2004, 29(1): 38-39.
[5]	王洪亚 , 韩啸 , 王子安 . 紫杉醇联合顺铂治疗中晚期非小细胞肺癌34例分析. 蚌埠医学院学报, 2009, 34(8): 682-684.
[6]	金建华 , 王芳 , 陆文斌 , 赵宏祥 , 倪晓谦 . 多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察. 蚌埠医学院学报, 2005, 30(6): 513-515.
[7]	夏晓阳 , 叶爱和 , 陈爱民 , 尤冬山 . 吉西他滨联合顺铂治疗晚期非小细胞肺癌42例观察. 蚌埠医学院学报, 2007, 32(5): 551-553.
[8]	赵林芳 , 何彬 , 杨春红 , 许金花 . 长春瑞滨联合顺铂治疗肺胚细胞瘤1例护理. 蚌埠医学院学报, 2011, 36(6): 668-669.
[9]	孙惠娟 , 秦凤展 , 郑荣生 , 汪子书 , 王洪亚 , 刘铁成 . 多西他赛联合顺铂治疗晚期乳腺癌临床观察. 蚌埠医学院学报, 2006, 31(5): 468-469.
[10]	蒋鹏程 , 周蓓蓓 , 董丽萍 , 周晨 . 放疗联合顺铂化疗治疗Ⅲ期子宫颈癌疗效分析. 蚌埠医学院学报, 2006, 31(6): 637-639.
[11]	杨维芹 . 术前使用顺铂联合不同药物治疗宫颈癌的疗效比较. 蚌埠医学院学报, 2013, 37(8): 998-999.
[12]	赵伟庆 , 季枚 , 吴昌平 . 国产紫杉醇联合顺铂治疗晚期非小细胞肺癌40例疗效观察. 蚌埠医学院学报, 2006, 31(2): 146-148.
[13]	齐晓艳 , 张翠玲 . 缝隙连接细胞间通讯对顺铂疗效的影响研究进展. 蚌埠医学院学报, 2012, 36(3): 370-372.
[14]	吕和力 . 抑制USP22表达对胶质瘤细胞顺铂耐药的影响. 蚌埠医学院学报, 2020, 45(4): 452-455, 460. doi: 10.13898/j.cnki.issn.1000-2200.2020.04.008
[15]	吴宣宣 , 张俊丽 , 商玲 , 燕善军 , 武文娟 . 低分子质量肝素联合顺铂对肝癌细胞自噬的影响. 蚌埠医学院学报, 2023, 48(4): 426-431. doi: 10.13898/j.cnki.issn.1000-2200.2023.04.002
[16]	翟云芝 , 陈振东 . 多西他赛联合顺铂治疗蒽环类耐药晚期乳腺癌疗效分析. 蚌埠医学院学报, 2007, 32(3): 291-292.
[17]	刘玲玲 , 张梦晓 , 张配 , 赵素容 , 刘浩 . 褪黑素联合顺铂对人食管癌Eca109细胞的抑制作用及其机制. 蚌埠医学院学报, 2016, 41(3): 281-283. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.001
[18]	潘明 , 郑中显 , 徐金发 , 刘飞 , 宋文灿 . 紫杉醇联合顺铂、氟尿嘧啶治疗晚期上消化道癌43例临床分析. 蚌埠医学院学报, 2007, 32(4): 451-452.
[19]	李多杰 , 李红伟 , 段诗苗 , 崔珍 , 彭开桂 , 沈学明 . 放疗联合顺铂、氟尿嘧啶方案同步治疗局部晚期食管癌的效果观察. 蚌埠医学院学报, 2012, 36(2): 153-156.
[20]	苏凯 , 赵报 , 马莹晔 , 李慧 , 周帅 , 王晓敏 , 张俊杰 , 马士崟 . Vγ9Vδ2 T细胞联合顺铂增强对鼻咽癌细胞的杀伤作用. 蚌埠医学院学报, 2022, 47(11): 1479-1483. doi: 10.13898/j.cnki.issn.1000-2200.2022.11.001

点击查看大图

计量

文章访问数: 3682
HTML全文浏览量: 313
PDF下载量: 409
被引次数: 0

培美曲赛联合铂类治疗晚期非小细胞肺癌的安全性和有效性观察

作者简介: 孙翠玲(1974-),女,副主任医师.

安徽省阜阳市人民医院肿瘤科, 236000

收稿日期: 2014-05-28

关键词:

摘要: 目的:探讨培美曲赛对初治或复治晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的安全性和有效性。方法:经病理学或细胞学确诊的晚期NSCLC患者41例, 其中一线治疗18例, 二线治疗23例。培美曲赛500 mg/m²(第1天)+顺铂25 mg/m²(第2、3、4天)或卡铂AUC=5(第1天)静脉滴注, 每3周为1个周期;评价安全性及有效性。结果:18例一线治疗患者中无完全缓解病例, 部分缓解7例, 稳定4例, 进展7例, 有效率38.89%, 疾病控制率61.11%, 中位无疾病进展时间6.8个月。23例二线治疗患者中无完全缓解病例, 部分缓解2例, 稳定9例, 进展12例, 有效率8.70%, 疾病控制率47.83%, 中位无进展生存时间2.6个月。2组主要不良反应为乏力、白细胞下降、贫血和胃肠道反应。结论:培美曲赛联合铂类方案一线、二线治疗晚期NSCLC疗效确切, 安全性高, 耐受性较好。

English Abstract

Safety and effectiveness of pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer

Department of Oncology, The People's Hospital of Fuyang, Fuyang Anhui 236000, China

Received Date: 2014-05-28

Abstract: Objective:To investigate the safety and effectiveness of the pemetrexed in the treatment of the initial or recurrent advanced non-small cell lung cancer(NSCLC).Methods:The 18 cases of the first-line treatment and 23 cases of the secondary-line treatment in 41 cases with advanced NSCLC identified by pathology or cytology were treated with 500 mg/m² of pemetrexed at the first day combined with 25 mg/m² of cisplatin at 2, 3 and 4 days or 5 AUC of carboplatin at the first day by intravenous drip, 3 weeks for a course.The safety and effectiveness of treatment were evaluated.Results:Partial response in 7 cases, stabilization in 4 cases, progress in 7 cases and no complete response cases in 18 cases with the first-line treatment were found, the effective rate and disease control rate were 38.89% and 61.11%, respectively, and the median progression-free survival time of which was 6.8 months.Partial response in 2 cases, stabilization in 9 cases, progress in 12 cases and no complete response cases in 23 cases with the second-line treatment were found, the effective rate and disease control rate were 8.70% and 47.83%, respectively, and the median progression-free survival time of which was 2.6 months.The major adverse reactions in two groups included fatigue, white blood cells decreasing, anemia and gastrointestinal tract reaction.Conclusions:The effects of pemetrexed combined with platinum in the first-line and second-line treatment of advanced NSCLC are good, high safety and good tolerance.